4 Corporate Drive, Andover, MA
About the project
Hereva was hired to be Owner’s Project Manager for Oncorus’ multiphase expansion project, and we have been involved from the initial property search, including creation of the Master Schedule, budget, site selection and lease negotiation, programming, stage-gate approvals, managing the development team, procurement, relocation and operational startup. We helped select the design team, and will continue through project completion and operational startup. We also helped the team to create new P&ID (Piping and Instrumentation Diagrams).
Oncorus, whose R&D headquarters will remain in Cambridge, signed a lease in Innovation Park in Andover with the goal of transforming the current facility into an additional location for GMP clinical manufacturing, while strengthening its corporate brand and regional presence as a global leader in cancer treatment. This will be the first GMP facility for Oncorus.
The Project will be in a multi-tenant building that has not previously housed GMP operations. The facility is intended to provide a comprehensive solution for Oncorus’ Chemistry, Manufacturing and Controls (CMC) development needs, enabling the manufacture, quality, control and supply of clinical-grade viral immunotherapies for investigational new drugs.
Our biggest challenge so far is in building out clean room suites for a process that has not yet been defined. The first phase of the project is the limited renovation of 17,000 sf of lab facilities to be completed on or about July 2021. The next phase will consist of the ground level and first floor loading dock and office space (16,000sf) starting in Q2 2021 followed by the first floor cGMP facility (42,000 sf) starting in November 2021. Total project completion is on schedule for the end of 2022.
Oncorus is focused on driving innovation to deliver next-generation viral immunotherapies to transform outcomes for cancer patients. They are advancing a portfolio of intratumorally and intravenously administered viral immunotherapies for multiple indications with significant unmet needs based on their oncolytic Herpes Simplex Virus (oHSV) Platform and Synthetic Virus Platform. Please visit www.oncorus.com to learn more.